Risk Factors Update Summary
- The ongoing armed conflict in Israel and the Gaza Strip may impact clinical trial sites.
- Enrollment in Phase 3 clinical trials may be affected by marketing approval for investigational MASH drugs.
- The company raised gross proceeds of $230.0 million from a follow-on public offering in September 2023.
- The company reported net losses of $151.8 million, $112.0 million, and $100.8 million for 2023, 2022, and 2021, respectively.
- The company had 38 full-time employees as of February 2023, increased from 55 employees.
- The company had accumulated deficits of $422 million as of December 31, 2023, increased from $574 million.
- The company had U.S. federal net operating loss carryforwards of $248 million and $235 million for 2022 and 2023, respectively.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1744659&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.